View 
FILTERS (0)
* Not connected to ResearchPool

MORE FILTERS

  
reports
 PRESS RELEASE

The Lovesac Company Appoints Heidi Cooley as Chief Brand and Marketing...

The Lovesac Company Appoints Heidi Cooley as Chief Brand and Marketing Officer Seasoned Executive and Proven Brand Strategist to Accelerate the Company’s Next Chapter of Growth STAMFORD, Conn., April 10, 2025 (GLOBE NEWSWIRE) -- The Lovesac Company (Nasdaq: LOVE) (“Lovesac” or the “Company”), the Designed for Life home and technology brand, today announced the appointment of Heidi Cooley as Chief Brand and Marketing Officer, effective April 23, 2025. Ms. Cooley will be the first Chief Brand and Marketing Officer for Lovesac and will lead all aspects of marketing, eCommerce and brand str...

 PRESS RELEASE

The Lovesac Company Reports Fourth Quarter And Fiscal 2025 Financial R...

The Lovesac Company Reports Fourth Quarter And Fiscal 2025 Financial Results Fourth Quarter Net Sales of $241.5 million Fiscal Year Net Sales of $680.6 million STAMFORD, Conn., April 10, 2025 (GLOBE NEWSWIRE) -- The Lovesac Company (Nasdaq: LOVE) (“Lovesac” or the “Company”), the Designed for Life home and technology brand best known for its Sactionals, The World's Most Adaptable Couch, today announced financial results for the fourth quarter and full year fiscal 2025, which ended February 2, 2025. Note: Lovesac's prior year fourth quarter and fiscal 2024 results contain an additional,...

 PRESS RELEASE

Genelux Corporation Reports Fourth Quarter and Full Year 2024 Financia...

Genelux Corporation Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update – Alignment reached with U.S. Food and Drug Administration on key elements of the approval pathway for Olvi-Vec in Platinum Resistant/Refractory Ovarian Cancer – – Positive Preliminary Phase 1b/2 Data of Olvi-Vec in Advanced Small-Cell Lung Cancer – – Matt Pulisic joined the company as its new Chief Financial Officer – – Closing of $10.5 Million Underwritten Offering of Common Stock – – $30.9 million in cash, cash equivalents and short-term investments – WESTLAKE VILLAGE, Calif....

 PRESS RELEASE

The Lovesac Company Announces Fourth Quarter and Fiscal 2025 Conferenc...

The Lovesac Company Announces Fourth Quarter and Fiscal 2025 Conference Call Date STAMFORD, Conn., March 27, 2025 (GLOBE NEWSWIRE) -- The Lovesac Company (Nasdaq: LOVE) (“Lovesac” or the “Company”), the Designed for Life home and technology brand, today announced that its fourth quarter and fiscal 2025 financial results will be released before market open on Thursday, April 10, 2025. The Company will host a conference call at 8:30 a.m. Eastern Time to discuss the financial results. Investors and analysts interested in participating in the call are invited to dial 877-407-3982 (internatio...

 PRESS RELEASE

Genelux Corporation Announces Pricing of $10.5 Million Underwritten Of...

Genelux Corporation Announces Pricing of $10.5 Million Underwritten Offering of Common Stock WESTLAKE VILLAGE, Calif., March 25, 2025 (GLOBE NEWSWIRE) -- Genelux Corporation (“Genelux”) (Nasdaq: GNLX), a late clinical-stage immuno-oncology company, today announced the pricing of an underwritten offering of 3,000,000 shares of its common stock at an offering price of $3.50 per share. The gross proceeds to Genelux from the offering are expected to be $10.5 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by Genelux. Titan Partners G...

 PRESS RELEASE

Genelux and Newsoara Announce Positive Preliminary Phase 1b/2 Data of ...

Genelux and Newsoara Announce Positive Preliminary Phase 1b/2 Data of Olvi-Vec in Advanced Small-Cell Lung Cancer –  Systemic administration of Olvi-Vec in the initial dose escalation cohorts achieved a 71% disease control rate (5/7) with two partial responders. All participants with disease control experienced a reduction in all target lesions, with one participant achieving a tumor reduction of approximately 79%. –  Additionally, three participants, including one individual with three prior lines of treatment, achieved stable disease at lower dose cohorts, with tumor size reductions ra...

 PRESS RELEASE

Genelux Announces Alignment with FDA on Key Elements of the Approval P...

Genelux Announces Alignment with FDA on Key Elements of the Approval Pathway for Olvi-Vec in Platinum Resistant/Refractory Disease - U.S. Food and Drug Administration states that data from the ongoing OnPrime/GOG-3076 Phase 3 registrational trial could potentially support traditional approval - WESTLAKE VILLAGE, Calif., March 25, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that Genelux has concluded a productive Type D meeting with the U.S. Food and Drug Administration (FDA) for Olvi-Vec in the treatment of platinum resistant/r...

 PRESS RELEASE

Genelux Corporation Announces New Chief Financial Officer

Genelux Corporation Announces New Chief Financial Officer WESTLAKE VILLAGE, Calif., Feb. 03, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that Matthew Pulisic has joined the company as its new Chief Financial Officer, effective January 30, 2025. "I am very pleased to welcome Matt as our new Chief Financial Officer. Matt’s financial acumen, strategic mindset and proven leadership abilities are an ideal fit for Genelux,” said Thomas Zindrick, President, CEO and Chairman of the Board. “His unique combination of financial expertis...

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights Weekly Report: January 18, 2025

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights Weekly Report: January 11, 2025

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

 PRESS RELEASE

The Lovesac Company Announces Participation in the 2025 ICR Conference

The Lovesac Company Announces Participation in the 2025 ICR Conference STAMFORD, Conn., Jan. 07, 2025 (GLOBE NEWSWIRE) -- The Lovesac Company (Nasdaq: LOVE) (“Lovesac” or the “Company”), the home furnishing brand best known for its Sactionals, The World's Most Adaptable Couch, today announced that the Company is scheduled to participate in the 2025 ICR Conference on Tuesday, January 14, 2025, at 11:00 a.m. Eastern Time. The fireside chat will be webcast live over the Internet and can be accessed on the Company’s Investor Relations website, investor.lovesac.com. An online archive will be ...

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights Weekly Report: January 4, 2025

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights Weekly Report: December 28, 2024

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

 PRESS RELEASE

The Lovesac Company Publishes 2024 ESG Report

The Lovesac Company Publishes 2024 ESG Report STAMFORD, Conn., Dec. 20, 2024 (GLOBE NEWSWIRE) -- The Lovesac Company (Nasdaq: LOVE) (“Lovesac” or the “Company”), the home furnishing brand best known for its Sactionals, The World's Most Adaptable Couch, has released its ESG & Impact Report for the 2024 fiscal year ended February 4, 2024. This report highlights the company's continued commitment to environmental sustainability, social responsibility, and governance (“ESG”). Shawn Nelson, Chief Executive Officer, stated, “Lovesac’s commitment to sustainability and responsible business pract...

 PRESS RELEASE

The Lovesac Company Details Strategic Framework and Multi-Year Financi...

The Lovesac Company Details Strategic Framework and Multi-Year Financial Algorithm at Investor Day STAMFORD, Conn., Dec. 17, 2024 (GLOBE NEWSWIRE) -- The Lovesac Company (Nasdaq: LOVE) (“Lovesac” or the “Company”), the home furnishing brand best known for its Sactionals, The World's Most Adaptable Couch, will host an Investor Day today, December 17, 2024, at 10:00 am ET. Interested parties may access the webcast of the event, related published materials and a replay of the event by accessing Lovesac’s IR website at . The event will feature presentations by members of Lovesac’s leadersh...

 PRESS RELEASE

Genelux Corporation to Participate in a Fireside Chat with H.C. Wainwr...

Genelux Corporation to Participate in a Fireside Chat with H.C. Wainwright WESTLAKE VILLAGE, Calif., Dec. 13, 2024 (GLOBE NEWSWIRE) -- (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that , President, CEO and Chairman of the Board will participate in a virtual fireside chat with H.C. Wainwright & Co. on December 16, 2024. Biotech Equity Research Analyst, Emily Bodnar, will moderate the HCW@Home session which is scheduled to begin at 11:00 a.m. ET. The discussion will focus on the company’s clinical program of its lead candidate, Olvi-Vec, including its o...

 PRESS RELEASE

The Lovesac Company Reports Third Quarter Fiscal 2025 Financial Result...

The Lovesac Company Reports Third Quarter Fiscal 2025 Financial Results Q3 FY25 Net Sales of $149.9 Million STAMFORD, Conn., Dec. 12, 2024 (GLOBE NEWSWIRE) -- The Lovesac Company (Nasdaq: LOVE) (“Lovesac” or the “Company”), the home furnishing brand best known for its Sactionals, The World's Most Adaptable Couch, today announced financial results for the third quarter of fiscal 2025, which ended November 3, 2024. Shawn Nelson, Chief Executive Officer, stated, “Near-term headwinds for our category clearly persisted through the pre-election period. However, we gained market share and str...

 PRESS RELEASE

The Lovesac Company Announces Third Quarter Fiscal 2025 Conference Cal...

The Lovesac Company Announces Third Quarter Fiscal 2025 Conference Call Date STAMFORD, Conn., Dec. 05, 2024 (GLOBE NEWSWIRE) -- The Lovesac Company (Nasdaq: LOVE) (“Lovesac” or the “Company”), the Designed for Life home and technology brand, today announced that it will release its financial results for the third quarter of fiscal 2025 before market open on Thursday, December 12, 2024. The Company will host a conference call at 8:30 a.m. Eastern Time to discuss the financial results. Investors and analysts interested in participating in the call are invited to dial 877-407-3982 (internat...

 PRESS RELEASE

Genelux Corporation Reports Third Quarter 2024 Financial Results and P...

Genelux Corporation Reports Third Quarter 2024 Financial Results and Provides General Business Updates WESTLAKE VILLAGE, Calif., Nov. 14, 2024 (GLOBE NEWSWIRE) -- (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced financial results for the third quarter of 2024 and provided general business updates. The Company initiated its second lung cancer trial, a US-based, Phase 2 trial (VIRO-25) treating patients with recurrent advanced or metastatic non-small cell lung cancer (NSCLC) with Olvi-Vec, followed by platinum-doublet chemotherapy + immune checkpoint inhi...

Loading...
New interest

Save your current filters as a new Interest

Please enter a name for this interest

Email alerts

Would you like to receive real-time email alerts when a new report is published under this interest?

Save This Search

These search results will show up under 'Saved searches' in the left panel

Please enter a name for this saved search

ResearchPool Subscriptions

Get the most out of your insights

Get in touch